Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EOS100850 · 1 trial · 1 indication
To define the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) of EOS100850 in patients receiving EOS100850
To assess safety and tolerability as measured by incidence and severity of AEs
| Arm | Type | Description |
|---|---|---|
| 1A Dose escalation EOS100850 | EXPERIMENTAL | Dose Escalation- EOS100850 Monotherapy: to confirm RP2D |
| 1B Dose escalation EOS100850 and Pembrolizumab | EXPERIMENTAL | EOS100850 and Pembrolizumab Combination Therapy: to confirm RP2D as combination |
| 2A Dose Expansion- EOS100850 | EXPERIMENTAL | Dose Expansion - EOS100850 Monotherapy: to explore safety, PK, PD, and antitumor activity of inupadenant as monotherapy |
| 2B Dose Expansion - EOS100850 and Pembrolizumab | EXPERIMENTAL | Dose Expansion - EOS100850 and Pembrolizumab Combination Therapy: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with pembrolizumab in melanoma and CRPC patients |
| 2D Dose expansion - EOS100850 and Chemotherapy in TNBC | EXPERIMENTAL | Dose expansion - EOS100850 and Chemotherapy Combination: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with chemotherapy SOC carboplatin and paclitaxel in patients with TNBC |
| 3 EOS100850 in BMK-H participants | EXPERIMENTAL | Dose expansion - EOS100850 Monotherapy : to evaluate the safety, PD, and antitumor activity of inupadenant as monotherapy at the mono-RP2D in BMK-H participants in 4 disease-specific cohorts: NSCLC; HNSCC; EC; and other forms of cancer |
| Name | Type | Description |
|---|---|---|
| EOS100850 | DRUG | Oral administration |
| Pembrolizumab | DRUG | IV Infusion |
| Chemotherapy | DRUG | Standard of Care IV Infusion |
For more information regarding participation in the Trial, please refer to your physician Inclusion Criteria: * Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Subject with histologically or cytologically confirmed advanced solid tumor f...
EOS100850 is an investigational small molecule being studied for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development, with a completed first-in-human trial that enrolled 119 patients. The drug is not yet approved and remains under investigation.
EOS100850 is a small molecule developed by iTeos Therapeutics. Its specific molecular target has not been disclosed in the available information. The drug is being evaluated for its potential in oncology, specifically for solid tumors in adult patients.
EOS100850 is developed by iTeos Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker ITOS. The company is conducting clinical research on this investigational small molecule for the treatment of solid tumors.
EOS100850 is in Phase 1 clinical development. A first-in-human study (NCT03873883) has been completed, involving 119 patients with solid tumors. The drug is investigational and has not received regulatory approval.
EOS100850 has one completed clinical trial, NCT03873883, titled 'First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer.' This Phase 1 study enrolled 119 adults with solid tumors across the United States, Belgium, France, South Korea, Spain, and the United Kingdom.
Yes, EOS100850 is also known as Inupadenant. The completed clinical trial NCT03873883 refers to the drug as EOS100850 (Inupadenant), confirming that these names refer to the same investigational small molecule being developed by iTeos Therapeutics.